MLEC
Moolec Science SA
NASDAQ · Healthcare · Biotechnology · LU
$6.10
−2.09%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -99.1%
- EBITDA
- -36.2%
- EPS
- +85.5%
Three-year CAGR
- Revenue
- +1819.9%
- EBITDA
- —
- EBIT
- -15.9%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2025